| To: bmaz001 who wrote (672) | 1/11/2023 2:33:55 PM | | From: Area51 | | | | Thanks. Do you (or other thread followers) have some favorites per chance? Something that not only trades below Net current asset value, but also has good prospects for being profitable in the not so distant future?
Failing that if we assume they have no debt (not always true) I guess we can look at (market cap - Enterprise Value)/ market cap and sort on the result and look at the top 10 or 20. Would help if the spreadsheet would let us copy and paste it to an excel spreadsheet, but that ability seems to be disabled? Too many listed for me to do a 100% review I think <g>. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: Area51 who wrote (673) | 1/11/2023 3:21:19 PM | | From: bmaz001 | | | | I've unlocked the 'Less Than Cash' workbook so you can download it to Excel or copy-n-paste into your own Google Sheets space.
I don't have any favorites to share but you might consider looking at some of the portfolios that were entered for the '2023 Biotech Charity Contest' subject here on SI. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Area51 who wrote (673) | 1/16/2023 1:15:11 PM | | From: Bladerunner17 | | | | From the list I own CRDF and CRIS. Needless to say, I've gotten killed on both of them, but I still like their prospects.
Bladerunner |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: bmaz001 who wrote (674) | 2/6/2023 12:25:07 PM | | From: Area51 | | | | Thanks! Great list. When I did sort the list (by an estimate of cash/ market-cap) I think IMAB and GRCL (Chinese listed) came out on top. But likely in error, as IMAB had 574 million in cash in USD as of last report so highly unlikely that their EV is negative 3400 million as the spreadsheet lists (They do have about 3900 million cash in RMB so maybe that is what the spreadsheet is pulling in for cash?). I still bought a (very) little IMAB today as it fell to the $5 area.
top of sorted list based on early january market cap:
| Ticker | Country | Market Cap (M) | EV | Cash (Est) | Short % of Float | Cash (% of MC) | | GRCL | China | 150.3 | -1275.6 | 1425.9 | | 949% | | IMAB | China | 442.9 | -3375.3 | 3818.2 | | 862% | | NEXI | United States | 9.4 | -35.3 | 44.7 | 1.80% | 476% | | SGTX | United States | 11.7 | -36 | 47.7 | 0.80% | 408% | | NXTC | United States | 44.2 | -125.1 | 169.3 | 1.50% | 383% | | TALS | United States | 50.5 | -140.3 | 190.8 | 3.70% | 378% | | ELEV | United States | 21.2 | -57.4 | 78.6 | 0.30% | 371% | | ENVB | United States | 5.8 | -15.3 | 21.1 | 2.20% | 364% | | AMPE | United States | 4.5 | -11.7 | 16.2 | 1.50% | 360% | | PYXS | United States | 51.2 | -131.2 | 182.4 | 1.80% | 356% | | ACHL | United Kingdom | 48.7 | -122.2 | 170.9 | | 351% | | LMNL | Canada | 11.3 | -27.9 | 39.2 | 0.10% | 347% | | SLRX | United States | 5 | -11.9 | 16.9 | 1.60% | 338% | | BLCM | United States | 8.5 | -20.2 | 28.7 | 1.40% | 338% | | SRZN | United States | 21.5 | -50.8 | 72.3 | 0.60% | 336% | | SNPX | United States | 7.9 | -18.5 | 26.4 | 6.20% | 334% | | CELZ | United States | 6.6 | -15.4 | 22 | 1.40% | 333% | | MGTA | United States | 30.3 | -67.2 | 97.5 | 10.20% | 322% | | TCRX | United States | 32.9 | -70.5 | 103.4 | 0.90% | 314% | | MEIP | United States | 40 | -84.7 | 124.7 | 2.60% | 312% | | AEZS | United States | 17.4 | -36.3 | 53.7 | 2.00% | 309% | | AVRO | United States | 37.8 | -78.2 | 116 | 0.60% | 307% | |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Area51 who wrote (677) | 10/23/2023 7:45:52 PM | | From: JamesK | | | | | One that makes your list due to its decline is KOD. Has like cash 4 times market cap. Market cap used to be $8 Billion. Has to be one of the worst biotech implosions. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: JamesK | 10/28/2023 3:59:18 PM | | | | | | | FATE is another one that experienced a large loss after attaining a huge market cap. Serious wealth destruction. Cash is more than twice it's current market cap. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: JamesK who wrote (679) | 10/29/2023 6:01:50 PM | | From: A.J. Mullen | | | | Fate is interesting. I was tempted before the sell-off. It’s working on exciting stuff – off-the-shelf immunotherapies. At the beginning of the year, it chose to end rather than revise a collaboration with J&J which resulted in a termination fee to Fate of over $50m. They also announced a 50% reduction in headcount. It said it aimed to have a runway through 2025. Its cash is now approximately twice its current free-cash flow (including the termination fee).
Ashley |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: A.J. Mullen who wrote (680) | 10/30/2023 6:31:52 PM | | From: JamesK | | | | They are all so beaten down. I'm sure in five years they'll be so many, "I should have bought that one".
There are so many of these cell therapy companies, having a hard time knowing which to pick. They are starting to show some promise in treating autoimmune diseases with CAR-T. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: scaram(o)uche | 4/3/2024 2:25:58 PM | | | | | | We usually look for negative EVs after a prolonged sector drought. But we've had good sector performance since November, with exception of a recent rough spot.
Matt Gamber at Twitter has looked for negative EVs under these circumstances.....
twitter.com
(thread)
Of those issues he mentions, I took a position in CMRX. Yeah, the same CMRX that brought such CMV-related misery to investors.
ONC201 for recurrent H3 K27M-mutant high-grade glioma, a molecule derived from the Oncoceutics munch. Observed toxicity in trials to date, but nothing that has derailed it.
https://aacrjournals.org/cancerdiscovery/article/13/11/2370/729854/Clinical-Efficacy-of-ONC201-in-H3K27M-Mutant
This position was taken without knowledge of market size, the difficulty penetrating it, or competitors addressing it. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
